Published in Eur J Pediatr on August 12, 2008
Association of the components of the metabolic syndrome with non-alcoholic fatty liver disease among normal-weight, overweight and obese children and adolescents. Diabetol Metab Syndr (2009) 1.13
Obesity and air pollution: global risk factors for pediatric non-alcoholic fatty liver disease. Hepat Mon (2011) 1.02
First National Report on Aminotransaminases' Percentiles in Children of the Middle East and North Africa (MENA): the CASPIAN-III Study. Hepat Mon (2012) 1.00
Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol (2011) 0.89
Differential impact of impaired fasting glucose versus impaired glucose tolerance on cardiometabolic risk factors in multi-ethnic overweight/obese children. Eur J Pediatr (2010) 0.85
Multidisciplinary therapy reduces risk factors for metabolic syndrome in obese adolescents. Eur J Pediatr (2012) 0.83
Relationships of cardiorespiratory fitness with metabolic risk factors, inflammation, and liver transaminases in overweight youths. Int J Pediatr (2010) 0.83
Obesity and metabolic syndrome in 7-9 years-old Portuguese schoolchildren. Diabetol Metab Syndr (2010) 0.81
Metabolic predictors for early identification of fatty liver using doppler and B-mode ultrasonography in overweight and obese adolescents. Eur J Pediatr (2010) 0.78
Metabolic syndrome is common and persistent in youth-onset type 2 diabetes: Results from the TODAY clinical trial. Obesity (Silver Spring) (2015) 0.77
Screening for elevated risk of liver disease in preschool children (aged 2-5 years) being seen for obesity management. SAGE Open Med (2014) 0.76
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 109.13
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem (1972) 95.79
Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med (2006) 18.51
Obesity and the metabolic syndrome in children and adolescents. N Engl J Med (2004) 13.99
Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes (2001) 9.67
Prevalence of fatty liver in children and adolescents. Pediatrics (2006) 7.00
The metabolic syndrome in children and adolescents. Lancet (2007) 5.97
Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics (2005) 4.67
The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol (2006) 4.52
Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev (2006) 3.06
Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis (2006) 2.95
Prevalence of abnormal serum aminotransferase values in overweight and obese adolescents. J Pediatr (2000) 2.79
Body index measurements in 1996-7 compared with 1980. Arch Dis Child (2000) 2.77
Influence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics (2005) 2.55
Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child (2005) 2.52
Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes (2005) 2.42
Alanine aminotransferase levels and fatty liver in childhood obesity: associations with insulin resistance, adiponectin, and visceral fat. J Clin Endocrinol Metab (2006) 2.34
Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care (2006) 2.34
Are age references for waist circumference, hip circumference and waist-hip ratio in Dutch children useful in clinical practice? Eur J Pediatr (2005) 1.88
Blood pressure in childhood: pooled findings of six European studies. J Hypertens (1991) 1.68
Waist circumference, blood pressure, and lipid components of the metabolic syndrome. J Pediatr (2006) 1.62
Insulin resistance, metabolic syndrome, and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care (2007) 1.53
Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr (2006) 1.31
Prevalence of metabolic syndrome (MS) in children and adolescents with varying degrees of obesity. Clin Endocrinol (Oxf) (2007) 1.19
Metabolic syndrome in Turkish children and adolescents. Metabolism (2006) 1.08
Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism (2007) 1.00
A new tool, a better tool? Prevalence and performance of the International Diabetes Federation and the National Cholesterol Education Program criteria for metabolic syndrome in different ethnic groups. Eur J Epidemiol (2007) 0.95
Sex hormone binding globulin concentration as a prepubertal marker for hyperinsulinaemia in obesity. Arch Dis Child (2001) 0.82
Commentary: the importance of addressing the rise of overweight and obesity--progress or lack of action during the last fifty years? Int J Epidemiol (2005) 0.75
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis (2013) 4.03
Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol (2008) 3.43
Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med (2004) 3.26
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12
Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev (2006) 3.06
Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis (2006) 2.95
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. Diabetes Care (2007) 2.61
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol (2011) 2.24
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother (2012) 2.14
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia (2015) 2.13
Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet (2010) 2.08
Valsartan-induced improvement in insulin sensitivity is not paralleled by changes in microvascular function in individuals with impaired glucose metabolism. J Hypertens (2011) 2.04
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (2002) 1.84
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet (2005) 1.84
Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet (2004) 1.82
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes (2006) 1.74
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res (2007) 1.74
Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study. Drugs Aging (2010) 1.69
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res (2006) 1.65
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell (2011) 1.62
Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol (2009) 1.61
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol (2006) 1.60
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci (2005) 1.59
Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther (2005) 1.58
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother (2008) 1.58
Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet (2005) 1.57
Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol (2011) 1.55
Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol (2009) 1.54
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. AIDS (2003) 1.54
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care (2011) 1.53
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol (2010) 1.53
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res (2004) 1.51
The effects of fall-risk-increasing drugs on postural control: a literature review. Drugs Aging (2013) 1.50
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol (2003) 1.49
Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology (2007) 1.49
Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum (2012) 1.48
Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol (2009) 1.45
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther (2005) 1.45
Gene variants in the novel type 2 diabetes loci CDC123/CAMK1D, THADA, ADAMTS9, BCL11A, and MTNR1B affect different aspects of pancreatic beta-cell function. Diabetes (2009) 1.44
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet (2003) 1.43
Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist (2006) 1.43
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin Cancer Res (2009) 1.42
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients. Eur Urol (2012) 1.41
Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study. Int J Cardiol (2012) 1.41
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer (2011) 1.40
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity. Mol Diagn Ther (2007) 1.39
Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation (2010) 1.39
Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol (2003) 1.39
Incretin mimetics as a novel therapeutic option for hepatic steatosis. Liver Int (2006) 1.37
Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci (2006) 1.36
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther (2008) 1.36
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res (2004) 1.35
Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) (2003) 1.34
Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet (2011) 1.33
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin Cancer Res (2003) 1.32
Clinical experience with aurora kinase inhibitors: a review. Oncologist (2009) 1.31
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol (2006) 1.29
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics (2008) 1.28
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev (2004) 1.28
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.28
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer (2005) 1.27
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.27
Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature. Curr Clin Pharmacol (2008) 1.26
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet (2006) 1.26
The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function. Eur Heart J (2008) 1.24
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients. Clin Cancer Res (2007) 1.24
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist (2005) 1.24
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol (2002) 1.23
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist (2007) 1.23
Dynamic cerebral autoregulation in acute lacunar and middle cerebral artery territory ischemic stroke. Stroke (2005) 1.21
Clinical proteomics in breast cancer: a review. Breast Cancer Res Treat (2008) 1.21
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther (2010) 1.21
Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol (2006) 1.21
Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care (2010) 1.21
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol (2006) 1.21
Magnetic resonance assessment of aortic pulse wave velocity, aortic distensibility, and cardiac function in uncomplicated type 2 diabetes mellitus. J Cardiovasc Magn Reson (2007) 1.21
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res (2002) 1.21
Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study. Diabetes (2009) 1.20
Slightly elevated B-type natriuretic peptide levels in a non-heart failure range indicate a worse left ventricular diastolic function in individuals with, as compared with individuals without, type 2 diabetes: the Hoorn Study. Eur J Heart Fail (2010) 1.19
Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol (2009) 1.18
Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data. BMC Bioinformatics (2008) 1.17
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res (2003) 1.17
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist (2008) 1.17
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res (2006) 1.17
The heritability of HbA1c and fasting blood glucose in different measurement settings. Twin Res Hum Genet (2008) 1.16
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn (2010) 1.16
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials (2005) 1.16
Overweight is highly prevalent in children with type 1 diabetes and associates with cardiometabolic risk. J Pediatr (2010) 1.15